MDM2 and prostate adenocarcinoma: Analysis of The Cancer Genome Atlas (TCGA) PanCancer dataset42 revealed higher expression of IL-6R and MDM2 mRNA in prostate adenocarcinomas with unaltered TP53 than in tumors with putative driver TP53 mutation, while STAT3 mRNA expression levels showed no difference depending on TP53 status (Fig. 6b).